12:00 AM
 | 
Jun 15, 2015
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Bayer sales and marketing update

The U.K.’s NICE issued draft guidance recommending Xofigo radium-223 dichloride from Bayer to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases who have received treatment with docetaxel. The committee recommended the drug only when Bayer provides it at an undisclosed discount under a patient access scheme. ...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >